Skip to content
Global sound
The Bio Report

The Bio Report

by Levine Media Group

Latest episode
Making an RNA Detour Around an Undruggable Target

About this podcast

The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.

Episodes

The newest 50 of 641 episodes

  • Making an RNA Detour Around an Undruggable Target · 23 min · Episode 197Some cancer-driving proteins offer few ways for conventional drugs to target, leaving patients with limited options even when researchers understand what fuels their tumors…
  • Making Opioids a Last Resort · 36 min · Episode 202Pain is one of medicine’s most common complaints, yet finding effective alternatives to opioids has proved remarkably difficult. Latigo Biotherapeutics is developing experimental…
  • Capitol Gains: Confronting Biotech’s Policy Risks · 45 min · Episode 201Biotech investors have long considered scientific uncertainty, clinical setbacks, and commercial risk when making investments. John Stanford, founder and executive director of…
  • Developing an Off-the-Shelf Cell-Based Immunotherapy for Metastatic Breast Cancer · 41 min · Episode 200For patients with metastatic breast cancer, successive treatments can lose effectiveness as tumors evolve and resistant cancer cells survive, leaving those who have received…
  • A Gut-Level Pivot from Diabetes to a GLP-1 Off-Ramp · 36 min · Episode 196GLP-1 medicines have transformed obesity treatment, but what happens when patients stop taking them? For Fractyl Health, the challenge of preventing weight regain has become the…
  • Targeting Residual Inflammation in Cardiovascular Disease · 42 min · Episode 195Cardiovascular disease remains the world's leading cause of death, yet many patients still face substantial risks even after conventional factors such as LDL cholesterol and…
  • Neutralizing Tumor Acidity to Improve Cancer Immunotherapy · 38 min · Episode 194Many cancer treatments fail not because immune cells can’t recognize a tumor, but because the hostile environment surrounding it can prevent them from doing their job. Dyve…
  • How a Breast-Milk-Derived Peptide Could Change Bladder Cancer Care · 26 min · Episode 193For people with non-muscle-invasive bladder cancer, treatment can involve repeated procedures, a high risk of tumor recurrence, toxic therapies and, in some cases, removal of the…
  • Targeting Visceral Fat with RNA Therapeutics · 29 min · Episode 192GLP-1 therapies have dramatically reshaped obesity care, but the next generation of medicines may be judged by more than how much weight patients lose. A central question is…
  • Engineering T-Cell Engagers for Solid Cancers · 32 min · Episode 191T-cell engagers have delivered important advances in blood cancers, but extending their success to solid tumors has proved considerably more difficult. Physical barriers…
  • Resetting Severe Allergies at Their Cellular Source · 33 min · Episode 190For people with severe allergies and mast cell diseases, the risk of a dangerous reaction can shape everyday decisions about food, activities, and family routines. Current…
  • Innovating ADCs with Dual Targeting and Smarter Delivery · 30 min · Episode 189Antibody-drug conjugates have established themselves as an important cancer-treatment modality, but their effectiveness and tolerability in solid tumors can be constrained by…
  • Targeting the Brain’s Immune System in Alzheimer’s Disease · 34 min · Episode 188Alzheimer’s disease remains one of medicine’s most intractable challenges. While existing therapies may address individual features of the disease, such as amyloid or tau, they…
  • How Gilead Is Building Durable Oncology and Immunology Franchises · 39 min · Episode 187Gilead today stands at an inflection point. Its HIV and broader virology business still account for roughly two-thirds of total revenue, even as oncology has grown into a…
  • Protecting the Brain After Stroke · 29 min · Episode 186Ischemic stroke remains one of the most devastating and resource‑intensive emergencies in medicine, with the physical removal of a clot, the current gold-standard care, still…
  • Turning the Thymus into an Engine of Immune Tolerance in T1D and Beyond · 38 min · Episode 185Type 1 diabetes is still a disease we manage day‑to‑day rather than prevent, and today’s approaches do little to stop the immune system from attacking beta cells in the first…
  • Unlocking Major Targets with Mini Proteins · 25 min · Episode 184Most small molecule drugs and biologics miss a large group of important receptors in the body. These receptors, known as GPCRs, play big roles in major diseases, but they are…
  • Addressing a Data Problem to Enable AI-Drug Discovery · 41 min · Episode 183AI’s promise in drug discovery is being held back by a simple but stubborn problem: the field doesn’t have enough of the right kind of lab-generated data to train good models…
  • Turning Multi Specific Antibody Design into an Engineering Discipline with AI · 30 min · Episode 182Multi-specific antibodies promise to unlock complex biology that conventional monoclonals can’t touch, but their added mechanisms of action also introduce safety and…
  • Addressing the Treatment Gap in Ischemic Stroke · 30 min · Episode 181Acute ischemic stroke is both ubiquitous and undertreated. Only a small fraction of patients currently receive clot-busting drugs or mechanical thrombectomy because of the small…
  • A Pipeline in a Product that Reimagines Control of Inflammation · 24 min · Episode 180Plasma gelsolin is an abundant, endogenous regulator of inflammation that is consumed during severe inflammatory insults. When levels fall too low, patients are at higher risk of…
  • Building a Genetics Engine to Crack the Target Bottleneck · 53 min · Episode 179A chronic shortage of high‑quality targets remains one of the biggest constraints in drug discovery, even as therapeutic tools become more powerful and diverse. Regeneron is…
  • Stopping Shape-Shifting Tumors with a First-in-Class Epigenetic Drug · 28 min · Episode 178Epigenetics, the layer of chemical switches that controls how genes are turned on and off, can act like cancer’s operating system when a single epigenetic enzyme becomes…
  • Rewriting the Rules of Antibody Drug Design · 38 min · Episode 177Most marketed antibodies work as antagonists, simply shutting off a receptor, even though many immune, metabolic, and cancer pathways require more nuanced control. Metaphore…
  • Mapping Cellular Stress Biology to Tackle Undruggable Targets · 30 min · Episode 176Cells continuously sense their environment and in response to stressors, adapt, recover, or die. Soley Therapeutics uses its AI platform to capture thousands of intracellular…
  • Turning Abandoned Drugs into Breakthroughs · 31 min · Episode 175Promising drugs can become abandoned or underused because of tolerability issues, poor drug‑like properties, or other fixable limitations, even when there is already compelling…
  • Targeting Cancer Survival Genes in Solid Tumors · 46 min · Episode 174Most cancer therapies hit one or a few pathways that tumors can escape by mutating, activating alternative survival routes, or pumping drugs out, leading to relapse and poor…
  • Addressing Treatment Gaps in Gout · 37 min · Episode 173Gout may be one of the oldest known forms of arthritis, but it remains widely misunderstood, undertreated, and a source of silent suffering for millions of people who are often…
  • An Off-the-Shelf Cell Therapy to Calm Cytokine Storms · 28 min · Episode 172Small molecule drugs and monoclonal antibodies often fall short at addressing severe inflammatory and immune‑mediated diseases. Mesoblast has spent more than 15 years…
  • Slowing Disability in MS · 29 min · Episode 171Most existing therapies for multiple sclerosis do a good job of reducing relapses and inflammatory activity, but they largely fail to stop the slow neurodegeneration that drives…
  • Tuning, Rather than Blocking, Immunity in IBD · 36 min · Episode 170The treatment of inflammatory bowel disease currently relies on immunosuppressive therapies that often lose effectiveness, carry infection risks, and drive high treatment…
  • Intercepting Cancer When DNA Surveillance Fails · 39 min · Episode 169Many people with the genetic condition Lynch syndrome live with the near‑certainty that they will one day develop cancer and have few options beyond constant screening and, in…
  • Targeting Psychosis in Alzheimer’s Disease · 22 min · Episode 168Alzheimer’s disease drug development has long focused on slowing memory loss, but for many families, the tipping point that makes home care impossible is not cognition—it is…
  • A Class Action Suits Moves RICO from Mobsters to Medicine · 43 min · Episode 167RICO, the Racketeer Influenced and Corrupt Organizations Act, was originally designed to prosecute organized crime. Today, it sits at the center of a landmark class action…
  • Outsmarting Resistance with Rhythm · 38 min · Episode 166Pancreatic cancer remains one of oncology’s deadliest diagnoses, with standard treatments often offering only transient tumor shrinkage at the cost of grueling side effects and…
  • Editing Away Autoimmunity at the HLA Source · 37 min · Episode 165Human leukocyte antigen, or HLA, genes, help the immune system tell the difference between the body’s own tissues and outside threats. In some people, certain versions of HLA…
  • Why Asia is the Emerging Epicenter for Global Biopharmaceutical Progress · 40 min · Episode 164Asia is quickly becoming a powerhouse for biopharma innovation, changing ideas about where breakthrough science and fast, cost-efficient drug development happen. A new McKinsey &…
  • Reprogramming Cancer from Within · 53 min · Episode 163Leukemia once threatened Aaron Viny’s life, but now it defines his mission. Diagnosed with acute lymphoblastic leukemia as a college student, he survived chemotherapy, central…
  • A Strategic Turn from Obesity to Cancer · 23 min · Episode 162When Amy Burroughs stepped in as CEO of Terns Pharmaceuticals, she not only had to fill a void created by the death of her predecessor, but also lead a strategic shift from an…
  • A One Two Gene Therapy Punch to Non-Muscle Invasive Bladder Cancer · 24 min · Episode 161A One‑Two Gene Therapy Punch to Non-Muscle Invasive Bladder Cancer Non–muscle invasive bladder cancer is a common, slow-progressing form of bladder cancer that makes up a…
  • Reprogramming T Cells to Cross the Brain’s Border · 39 min · Episode 160One of the challenges of treating brain tumors is delivering potent biologic therapies across the blood-brain barrier. Adaptin Bio has developed platform technology that…
  • A Billion-Dollar Bet on AI-First Drug Development · 47 min · Episode 159Despite the emergence of new modalities and drug development technologies, the cost and time to produce new therapies has changed little, and failure rates remain high. Xaira…
  • Finding New Targets on the Surface of Misfolded Proteins · 38 min · Episode 158Finding New Targets on the Surface of Misfolded One of the biggest hurdles in drug development is targeting proteins found in both healthy and diseased cells without triggering…
  • Targeting Tumors from the Inside Out · 27 min · Episode 157Systemic chemotherapy remains the foundation of cancer treatment, but its widespread toxicity too often cuts short potential therapeutic benefits. NanOlogy is developing a new…
  • An Effort to Detect and Treat Alzheimer’s at Its Earliest Stages · 29 min · Episode 156One of the challenges in treating the neurodegenerative condition Alzheimer’s disease is intervening early enough in the course of illness to provide meaningful benefit. AltPep…
  • The Year in Biotech and What’s Ahead for 2026 · 38 min · Episode 155Biotech stocks staged a dramatic turnaround in 2025, with the XBI well outpacing the S&P 500 despite concerns over leadership changes at the U.S. Food and Drug Administration…
  • Developing an Alternative to Opioids for Post-Surgical Pain · 26 min · Episode 154The approach to post-surgical pain relief has relied on short-duration treatments and notably opioids. That’s led to the associated risks of dependence and abuse, prolonged…
  • Leveraging the Power of Vocal Biomarkers · 22 min · Episode 153Physicians can learn a lot from talking to patients, and not just from the words they say, but from millions of data points from acoustic features of their speech, such as pitch…
  • Determining the Cause and Severity of Sepsis with a Point-of-Care Test · 37 min · Episode 152Sepsis remains one of medicine’s most intractable and costly problems, arising when an infection triggers a runaway immune response that damages organs long after a pathogen is…
  • Separating Signal from Noise in Regenerative Therapies · 32 min · Episode 151Rion is developing platelet-derived exosome therapeutics as off-the-shelf, room-temperature-stable alternatives to traditional cell therapies. The company’s lead program is…

Live, last hour: 8,110 songs on 4,507 stations in 131 countries

Discover the world through radio

More ways to discover (9)

Heard something good? Save it, or open it straight away in Spotify.

Radio 538 luisteren - Live!Popular right now